C5AR1 and cancer: Table 1 shows significant variations observed between the high- and low-C5aR1 groups for age, grade, status of MGMT promoter, IDH, and 1q/19q codeletion, with all associated p values being less than 0.001. No statistically significant differences were found for gender, radiotherapy, or chemotherapy between the two groups. Wilcoxon rank-sum testing revealed that C5aR1 expression was markedly elevated in the HGG samples compared to that seen in the normal para-cancer samples (p < 0.001; Figure 2a).